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Abstract: Many fungal quinazolinone metabolites, which contain the methyl-indole pyrazino
[1,2-b]quinazoline-3,6-dione core, have been found to possess promising antitumor activity.
The purpose of this work was to synthesize the enantiomeric pairs of two members of this
quinazolinone family, to explore their potential as antitumor and their ability to revert multidrug
resistance. The marine natural product fiscalin B (4c), and antienantiomers (4b, 5b, and 5c) were
synthesized via a one-pot approach, while the syn enantiomers (4a, 4d, 5a, and 5d) were synthetized
by a multi-step procedure. These strategies used anthranilic acid (i), chiral N-protected α-amino acids
(ii), and tryptophan methyl esters (iii) to form the core ring of pyrazino[2,1-b]quinazoline-3,6-dione
scaffold. Four enantiomeric pairs, with different enantiomeric purities, were obtained with overall
yields ranging from 7 to 40%. Compounds 4a–d and 5a–d were evaluated for their growth inhibitory
effect against two tumor cell lines. Differences between enantiomeric pairs were noted and 5a–d
displayed GI50 values ranging from 31 to 52 µM, which are lower than those of 4a–d. Nevertheless,
no effect on P-glycoprotein (P-gp) modulation was observed for all compounds. This study disclosed
new data for fiscalin B (4c), as well as for its analogues for a future development of novel anticancer
drug leads.
Keywords: antitumor; enantiomers; fiscalins; quinazolinones; synthesis
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1. Introduction
During the past ten years, great attention has been focused on drug development from Marine
Natural Products (MNPs) as well as on their synthetic and semi-synthetic analogues. While terrestrial
sources such as higher plants and microorganisms have reached the limelight, the marine environment
increasingly becomes the newest and untapped resource of bioactive compounds [1]. A number of
quinazolinone derivatives have played important roles in medicinal chemistry due to their broad
spectrum of biological properties such as antibacterial, antifungal, anticonvulsant, anti-inflammatory,
anti-HIV, anticancer, and analgesic activities [2,3]. One subclass of quinazolinone-derived Natural
Products are the indolylmethyl pyrazinoquinazoline alkaloids (1) (Figure 1), characterized by a fused
piperazine ring system linked to an indole moiety. So far, approximately 80 secondary metabolites
of this subclass, covering structurally diverse compounds, have been isolated from fungi, mainly of
marine origin. These include (i) compounds containing only a substituted piperazine ring such as
glyantrypine (2), isolated from the culture broth of the mangrove-derived fungus Cladosporium sp.
PJX-41 [4], fumiquinazoline F (3), isolated from the marine-derived fungus Aspergillus fumigatus
strain H1-04 and Aspergillus sp. [5,6], and fiscalin B (4), isolated from the culture of the fugal
strain Dichotomomyces cejpii which was recovered from sediments of the Brazilian coast [7]; (ii)
compounds with a more complex structure containing several rings such as fumiquinazoline K
(6), isolated from the Mediterranean sponge-derived fungus Aspergillus sp., the soft coral (Sinularia
sp.)-associated fungus Aspergillus fumigatus KMM 4631 [8], and a gorgonian-associated fungus [9]; (iii)
spiro compounds such as fumiquinazoline C (7), isolated from the marine-derived fungus Aspergillus
fumigatus strain H1-04, and N-formyllapatin A (8), isolated from the marine-derived fungus Penicillium
adametziodes (AS-53) [10]; (iv) compounds with complex 3-indolyl groups such as cladoquinazoline
(9) and epi-cladoquinazoline (10), isolated from the mangrove-derived fungus Cladosporium sp.
PJX-41 [4], neofiscalin A (11) from Neosartorya siamensis KUFC 6349, which was isolated from a
forest soil [11], as well as from N. siamensis KUFC 6349, isolated from the sea fan Rumphella sp. [12],
and fumiquinaziline S (12), isolated from a solid-substrate culture of Aspergillus sp., collected from a
marine-submerged wood [13]; or (v) compounds with indole glucosides such as fumigatoside A (13),
isolated from Aspergillus fumigatus which was derived from the jellyfish Nemopilema nomurai [14].
Marine alkaloids containing indolymethyl pyrazinoquinazoline ring system can be considered
conformationally constrained peptidomimetics exhibiting very interesting biological properties [15].
For instance, glyantrypine (2) is an antibacterial agent, active against Vibrio harveyi [16];
fumiquinazolines are antitumor compounds with moderate cytotoxicity [17]; fiscalins are substance
P inhibitors and anticancer agents [7,18]; cladoquinazolines (9 and 10) are active against influenza
A virus (H1N1); fumiquinazoline S (12) exhibits a weak inhibition against Na+/K+-ATPase, and
N-acetylardeemin (14) is a potent inhibitor of multidrug resistant (MDR) tumor cells [4,13,19,20].
Moreover, the pyrazino[2,1-b]quinazoline ring system has been already ascribed as essential for
the above-mentioned activities, and its enantioselective effects were observed for their antibacterial
activity. For example, neofiscalin A (11) showed potent antibacterial activity against Gram-negative
bacteria [12,21], whereas fiscalin C (15), epi-neofiscalin A (16), and epi-fiscalin C (17) were inactive in
the same study. Interestingly, fiscalin C (15) displayed a synergistic effect against methicillin-resistant
Staphylococcus aureus (MRSA) when combined with oxacillin [11,22]. Concerning antitumor activity,
studies on quinazolinone compounds have mainly focused on natural or synthetic compounds with
different substituents at the stereogenic C-1 and C-4; however, there is no report on analogues with
different configurations at C-1 and C-4.
Therefore, the aim of this study was to synthesize the diastereomers of fiscalin B (4c), i.e., 4a–d,
and their homologues 5a–d, to further explore their potential as growth inhibitors of tumor cells,
their ability to revert MDR by inhibiting P-gp activity, as well as to perform the SAR study.
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Figure 1. (A) Pyrazino[2,1-b]quinazoline-3,6-dione ring system (1) and some examples of the
marine-derived quinazolinone containing alkaloids (2–17) and (B) synthesized diastereomers of fiscalin
B and their homologues (4–5).
2. Results and Discussion
2.1. Synthesis of Pyrazinoquinazoline Alkaloids
The pyrazino[2,1-b]quinazoline-3,6-dione ring system (1) is the core structure of
fumiquinazoline-derived group of alkaloids. There are two main methods to synthesize compounds
containing this scaffold (i) the Eguchi-aza Wittig approach that consists of a selective acylation of
diketopiperazines with o-azidobenzoyl chloride, followed by dehydrative cyclization [23]; and (ii)
the Mazurkiewicz–Ganesan approach, consisting of coupling of linear tripeptides followed by the
isomerization of 4-imino-4H-3,1-benzoxozines to obtain the corresponding quinazolin-4-ones [24,25].
In 2005, Liu et al. [26] reported a highly effective and environmentally friendly approach using a
microwave-assisted multicomponent one-pot one step polycondensation of amino acids for the total
syntheses of glyantrypine (2), fumiquinazoline F (3), and fiscalin B (4). With this procedure, the
authors reported that the addition of a N-protected α-amino acid (ii) to anthranilic acid (i), under a
conventional heating condition at 55 ◦C with triphenylphosphite, (PhO)3P, generated the intermediate
benzoxazin-4-one, followed by the addition of tryptophan (Trp) ester (iii), and then submitted to
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microwave irradiation at 220 ◦C for 1.5 min, to furnish the desired final products. Inspired by this
simple and highly efficient methodology, we were able to prepare 4 and 5 (Scheme 1, method A).
Attempts to obtain the syn enantiomers by this one-pot approach failed since only vestigial amounts
could be detected due to the isomerization to the antienantiomers. The antienantiomers 4b/4c and
5b/5c were then obtained, starting from enantiomeric pure amino acids, from which no syn enantiomer
were isolated (Entry 1–8, Table 1). Therefore, the syn enantiomers 4a/d and 5a/d were synthesized
by the Mazurkiewicz–Ganesan method [25] (Scheme 1, method B) with some modifications. First,
coupling of i with iii, using 1,1,3,3-tetramethylaminium tetrafluoroborate (TBTU) in basic conditions,
afforded the dipeptide (iv). Coupling of iv with N-protected α-amino acids chloride (v) [27] in a
two-phase Schotten–Baumann condition yielded the tripeptides vi. The intermediates vii were
obtained by adding the dehydrating agent, triphenylphosphine (Ph3P), to convert β-keto amides (vi)
to the oxazoles (vii), followed by Fmoc-deprotection by 20% piperidine to afford 4a/d and 5a/d with a
moderate yields of 21–40%. After purification by chromatographic techniques, the purity of 4a–d and
5a–d, as determined by a reversed-phase HPLC (C18, MeOH:H2O; 60:40 or CH3CN:H2O; 50:50) was
found to be higher than 90% (Supplementary Materials, Figures S1–S8). The enantiomers ratio was
determined by the chiral HPLC equipped with amylose tris-3,5-dimethylphenylcarbamate column,
using hexane: ethanol (80:20) as a mobile phase (Table 1, Supplementary Materials, Figures S9–S16).
Table 1. Enantiomers and diastereomers of the pyrazinoquinazolinone alkaloids 4 and 5.
Entry R a Tryptophan % Anti Compound % Syn Compound [α]D b Enantiomeric Ratio c Purity (%) d
1 L-valine L-tryptophan 10 (4b) - +63.8 40:60 87
2 D-valine L-tryptophan 14 (4b) - +65.2 39:61 89
3 L-valine D-tryptophan 8 (4c) - −248.1 62:37 90
4 D-valine D-tryptophan 10 (4c) - −100.0 63:37 91
5 L-leucine L-tryptophan 7 (5b) - +44.9 67:33 94
6 D-leucine L-tryptophan 10 (5b) - +89.7 50:50 94
7 L-leucine D-tryptophan 8 (5c) - −61.7 31:69 90
8 D-leucine D-tryptophan 10 (5c) - −142.9 46:54 86
9 * L-valine L-tryptophan - 28 (4a) +300.5 100:0 94
10 * D-valine D-tryptophan - 21(4d) −210.5 7:93 89
11 * L-leucine L-tryptophan - 28 (5a) +81.8 90:10 89
12 * D-leucine D-tryptophan - 40 (5d) −186.0 17:83 85
a R residual of amino acid at C-1 position; b Optical rotation, concentration (g/100 mL); c Calculated from the
peak area from chiral HPLC experiments (by using equation X × 100/Xn in which X is the peak area of each peak
and Xn is the total peak area); d Calculated from the peak area from reversed-phase HPLC experiments;* Entry of
Mazurkiewicz–Ganesan approach.
The overall yield of this one-step method ranged from 7 to 14% with different enantiomeric
ratios (Table 1). The low yields of this one-pot reaction were attributed to a high temperature
applied in microwave irradiation to convert the intermediate Boc-protected-benzoxazin-4-one to
the final products. Moreover, the steric hindrance at C-1 could also be a reason, as previously
noted by Liu et al. [26] and Wang et al. [24] in the synthesis of similar compounds. Although a
partial epimerization was observed under these conditions, this one-pot procedure was proved
successful in providing the pyrazinoquinazolinone scaffold and a series of compounds for further
biological investigations. On the other hand, the moderate yields of compounds obtained by
Mazurkiewicz–Ganesan method were related to the mild conditions and a multistep approach
(Table 1 entry 9–12). In this study, the coupling agent 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
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(ECD) was replaced by TBTU, which gave a similar yield for the dipeptide iv (81–94%) when
compared to the previous reports. The tripeptides vi were also obtained in a very high yield
(84–94%). The bottleneck of this multistep approach was the conversion of the intermediates
vii to the final products since their decomposition to form the precursors vi, similar to what
has been previously report by Ganesan et al. [25], was observed. Compounds 4a/d and 5a/d
were purified by preparative TLC (EtOAc:CH2Cl2:MeOH: 50:47.5:2.5) after refluxing in CH3CN in
the presence of 4-(dimethylamino)pyridine. The degrees of epimerization of 4a/d and 5a/d by
Mazurkiewicz–Ganesan method were found to be lower than those obtained by the microwave
method (Table 1). These results could be also associated with the mild conditions used in the
multistep approach.
Scheme 1. Synthesis of the pyrazinoquinazolinone alkaloids 4 and 5. (Method A) One-pot
microwave-assisted approach. Reagents and conditions: (a) dried-pyridine, (PhO)3P, 55 ◦C, 16–24 h;
(b) dried-pyridine, (PhO)3P, 220 ◦C, 1.5 min; (Method B) Mazurkiewicz–Ganesan approach. Reagents
and conditions (a) CH3CN, TBTU, Et3N, rt, 5 h; (b) CH2Cl2/aq.Na2CO3, rt, 3 h; (c) dried CH2Cl2, Ph3P,
I2, EtN(i-Pr)2, rt, overnight; (d) piperidine in CH2CH2, rt, 12 min, then CH3CN, DMAP, reflux 19 h.
i-Pr = isopropyl; i-Bu = isobutyl, Boc = tert-butyloxycarbonyl; Fmoc = fluorenylmethyloxycarbonyl;
DMAP = 4-(dimethylamino) pyridine, TBTU = 1,1,3,3-tetramethylaminium tetrafluoroborate.
2.2. Structure Elucidation
The structures of the new compounds, 4a, 4b, and 4d, and of the synthetic fiscalin B (4c) and their
homologues 5a, 5b, 5d, and 5c, were established by extensive analyses of 1D and 2D NMR spectra
and high-resolution mass spectrometry. The 1H (Table 2, Supplementary Materials, Figures S17–S30)
and 13C NMR data (Table 3, Supplementary Materials, Figures S31–S44) of 4c were in agreement with
those reported in the literature for fiscalin B, which was obtained from the marine sources [24,25].
The chemical shift values of some key protons allowed the determination of the relative configurations
of both stereogenic centres as well as the conformation of the piperazine ring in 4 and 5, as shown
in 4a, 4b and 4c, 4d (Figure 2). The substituent on C-4 is always in a pseudoaxial position while
H-4 is shifted to δH 5.52–5.68 in all compounds, showing the characteristic anisotropic effect of the
coplanar carbonyl group at C-14 on the quasi-equatorial proton, as explained by Hernández et al. [28].
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The difference between anti and syn enantiomers were observed on H-1. In the antienantiomers,
the chemical shift value of the axial H-1 of 4b/c and 5b/c at δH 2.69–2.73 indicates the folding of the
C-4-indolyl substituent over the piperazine ring and the isopropyl group. This phenomenon was
also reported by Hernández and coworkers for H-1 signals of quinazolinones whose chemical shift
values were ca. 3 ppm for the boat conformation and the antienantiomers, due to the absence of
the shielding effect by the aromatic ring [28]. Meanwhile, for the syn enantiomers, 4a/d and 5a/d,
H-1 chemical shift values were at ca. δH 3.95–4.32, indicating the shielding effect from the aromatic
ring over H-1. The chemical shifts of H-1′ of the isopropyl group were also different between the anti-
and the syn enantiomers, being ca. δH 0.94–1.06 for 4a/d and δH 2.61–2.66 for 4c/d, indicating the
different shielding effect of the aromatic ring on the group on C-1.
Table 2. 1H NMR data (300 MHz, CDCl3) for 4 and 5.
Position
δH (J in Hz)
4a 4b 4c 4d
H-1 3.95, dd (8.4,3.5) 2.69, d (2.4) 2.69, d (2.4) 3.95, dd (8.5, 3.6)
H-2 6.50, d (3.0) 5.85, br 5.80, br 6.39, d (3.2)
H-4 5.52, dd (6.3, 3.8) 5.68, dd (5.0, 2.8) 5.67, dd (5.0, 2.8) 5.52, dd (6.3, 3.8)
H-8 8. 38, dd (8.0, 1.1) 8. 37, dd (8.0, 1.1) 8. 37, dd (8.0, 1.1) 8. 38, dd (8.0, 1.2)
H-9 7.54, ddd (8.2, 7.2, 1.2) 7.54, t (3.0) 7.54, t (5.2) 7.54, ddd (8.1, 7.3, 1.1)
H-10 7.79, ddd (8.7, 7.7, 1.9) 7.77, ddd (7.9, 7.7, 1.9) 7.77, ddd (8.9, 6.2, 1.9) 7.79, ddd (8.5, 7.1, 1.2)
H-11 7.62, d (7.7) 7.57, d (3.4) 7.57, d (3.5) 7.62, d (7.7)
H-1′ 1.06–0.94, m 2.66–2.61, m 2.66–2.61, m 1.06–0.94, m
H-2′ 0.48, d (6.6) 0.63, d (2.3) 0.63, d (4.0) 0.48, d (6.6)
H-3′ 0.75, d (6.8) 0.66, d (3.7) 0.65, d (4.3) 0.75, d (6.8)
H-4′a 3.72, dd (14.9, 3.7) 3.69, dd (15.0, 5.3) 3.69, dd (17.8, 4.0) 3.72, dd (14.8, 3.7)
H-4′b 3.80, dd (14.9, 6.3) 3.77, dd (15.0, 2.9) 3.77, dd (15.0, 2.8) 3.80, dd (14.8, 6.4)
H-6′ 6.89, d (2.4) 6.60, d (2.3) 6.60, d (2.4) 6.90, d (2.3)
H-7′ 8.06, br 8.03, br 8.03, br 8.03, br
H-9′ 7.28, d (8.4) 7.28, d (8.2) 7.28, d (8.2) 7.28, d (7.8)
H-10′ 7.10, ddd (8.6, 7.6, 1.0) 7.13, t (7.1) 7.13, t (7.1) 7.10, ddd (8.5, 7.5 0.9)
H-11′ 6.93, ddd (8.0, 7.1, 1.0) 6.93, t (7.5) 6.93, t (7.5) 6.94, ddd (8.2, 7.2, 1.0)
H-12′ 7.49, d (7.9) 7.44, d (8.0) 7.44, d (8.1) 7.49, d (7.9)
5a 5b 5c 5d
H-1 4.32, dt (10.7, 3.2) 2.73, dd (9.7, 3.4) 2.72, d (9.7) 4.31, dt (11.0, 3.2)
H-2 6.45, d (2.5) 5.75, br 5.75, br 6.21, d (2.5)
H-4 5.54, dd (5.2, 3.3) 5.68, dd (5.2, 3.0) 5.68, dd (5.0, 2.9) 5.55, dd (5.2, 3.3)
H-8 8. 39, dd (8.0, 1.2) 8. 37, d (8.0) 8. 37, d (8.0) 8. 39, dd (8.0, 1.1)
H-9 7.41, d (8.0) 7.55, d (8.1) 7.55, d (8.0) 7.42, d (8.0)
H-10 7.78, ddd (8.5, 7.2, 1.5) 7.78, ddd (8.5, 7.1, 1.5) 7.78, ddd (8.5, 7.1, 1.5) 7.79, ddd (8.5, 7.1, 1.6)
H-11 7.57, d (7.8) 7.60, d (7.8) 7.60, d (7.9) 7.59, d (7.8)
H-1′ 2.84–2.44, m 1.43–1.33, m 1.44–1.36, m 2.89–2.56, m
H-2′ 2.08–2.00, m 2.01, ddd (12.4, 12.5, 4.2) 2.01, dd (13.0, 9.4) 2.07–2.00, m
H-3′ 0.75, d (6.0) 0.77, d (6.4) 0.77, d (6.3) 0.74, d (6.0)
H-3” 0.49, d (6.1) 0.28, d (6.5) 0.28, d (6.4) 0.49, d (6.0)
H-4′a 3.75, dd (15.0, 3.3) 3.65, dd (15.0, 5.3) 3.65, dd (14.9, 5.2) 3.75, dd (15.1, 3.4)
H-4′b 3.83, dd (15.0, 5.3) 3.77, dd (15.0, 2.6) 3.78, dd (15.1, 2.8) 3.84, dd (15.0, 5.3)
H-6′ 6.68, d (2.3) 6.64, d (2.3) 6.64, d (2.0) 6.68, d (2.4)
H-7′ 8.08, br 8.09, br 8.07, br 8.03, br
H-9′ 7.28, d (8.1) 7.29, d (8.2) 7.29, d (8.2) 7.29, d (8.3)
H-10′ 7.12, ddd (8.5, 7.1, 1.1) 7.13, t (7.6) 7.13, t (8.0) 7.12, ddd (8.1, 7.0, 1.1)
H-11′ 6.97, ddd (8.5, 7.0, 1.1) 6.98, t (7.5) 6.98, t (7.5) 6.93, ddd (8.0, 7.1, 1.0)
H-12′ 7.53, ddd (8.1, 7.1, 1.0) 7.50, d (8.0) 7.50, d (8.0) 7.53, ddd (8.2, 7.2, 1.1)
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HMBC correlations were also used to distinguish the anti-isomers from the syn counterparts.
For the anti isomer 4b (whose indole moiety derived from L-Trp), H-4 exhibited correlations to C-14,
C-5′, C-4′, and C-3 whereas H-1 showed correlations to C-14, C-2′, C-3′, and C-1′. On the contrary,
in 4c (whose indole moiety is derived from D-Trp), the HMBC correlations from H-4 to C-14, C-5′,
C-4′ and from H-1 to C-14, C-3′, and C-2′, were observed. For the syn isomer 4a (whose indole
moiety derived from L-Trp), the HMBC correlations from H-1 to C-14, and from H-4 to C-14, C-4′,
and C-5′ were observed while the HMBC correlations from H-1 to C-3 and C-14 and from H-4 to
only C-4′ were observed in the syn isomer 4d. Moreover, the NOESY spectrum revealed the cross
peak between the C-1′ methyl groups and H-4 for the anti isomer 4c, while for the syn isomer 4a that
correlation was absent (Supplementary Materials, Figures S45–S46). These observations support the
identity/identification of the syn and anti conformational isomers.
Figure 2. Most relevant chemical shifts and key HMBC correlations of the protons to the stereogenic
centers on the piperazine ring of 4a–d.
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Table 3. 13C NMR data (75 MHz, CDCl3) for 4 and 5.
Position
δC, Type
4a 4b 4c 4d 5a 5b 5c 5d
C-1 61.9, CH 58.1 58.1 61.8 54.1, CH 50.8 50.8 54.1
C-3 167.8, CO 169.5 169.5 167.8 167.6, CO 169.4 169.4 167.5
C-4 57.5, CH 56.8 57.3 57.5 56.7, CH 57.3 57.3 56.7
C-6 161.4, CO 160.9 160.9 161.0 161.0, CO 160.8 160.8 161.1
C-7 120.2, C 120.2 120.2 120.2 120.4, C 120.3 120.3 120.0
C-8 126.8, CH 126.9 126.9 126.7 126.9, CH 126.9 126.9 126.8
C-9 127.1, CH 127.2 127.2 127.1 126.9, CH 127.4 127.4 126.8
C-10 134.7, CH 134.7 134.7 134.7 134.8, CH 134.6 134.6 134.7
C-11 127.1, CH 127.0 127.0 127.1 126.7, CH 127.1 127.1 126.7
C-12 146.8, C 147.1 147.1 146.1 147.2, C 147.0 147.0 147.2
C-14 149.3, C 150.3 150.3 149.8 151.3, C 151.5 151.5 151.3
C-1′ 34.5, CH 29.4 29.5 34.8 45.8, CH2 40.2 40.2 45.8
C-2′ 18.0, CH3 14.8 14.8 18.1 23.9, CH 24.1 24.1 23.9
C-3” - - - - 20.4, CH3 19.7 19.7 20.4
C-3′ 19.6, CH3 18.8 18.8 19.8 22.9, CH3 23.3 23.3 22.9
C-4′ 27.4, CH2 27.4 27.4 27.4 26.4, CH2 27.1 27.1 26.4
C-5′ 110.2, C 109.3 109.3 110.2 107.9, C 109.7 109.7 107.9
C-6′ 123.5, CH 123.6 123.6 123.6 123.6, CH 123.6 123.6 123.6
C-8′ 136.0, C 136.0 136.0 135.9 137.1, C 136.1 136.1 137.1
C-9′ 110.9, CH 111.1 111 111 110.2, CH 111.1 111.1 110.2
C-10′ 122.3, CH 122.6 122.6 122.4 122.2, CH 122.8 122.8 122.2
C-11′ 119.9, CH 120.0 120.0 119.9 119.9, CH 120.2 120.2 119.9
C-12′ 118.7, CH 118.7 118.7 118.7 119.0, CH 118.8 118.8 119.1
C-13′ 127.8, C 127.2 127.2 127.8 126.8, C 127.1 127.1 126.8
2.3. Tumor Cell Growth Inhibitory Activity
Compounds 4a–d and 5a–d were tested for their tumor cell growth inhibitory activity against
two human tumor cell lines: NCI-H460 (non-small cell lung cancer) and HCT-15 (colorectal
adenocarcinoma), using the sulforhodamine B (SRB) colorimetric assay [29]. Five serial dilutions
of each compound (at a maximum concentration of 150 µM) were tested for 48 h. Doxorubicin was
used as a positive control, and the antitumor activity was reported as GI50 (drug concentration that
inhibits the growth of cancer cells by 50%).
Compounds 4a–d, 5a, 5b, and 5d were also investigated for their possible modulatory activity
of P-gp, a drug efflux pump associated with drug resistance. P-gp activity was determined by an
assay which measures the mean fluorescence intensity of cells treated concomitantly with rhodamine
123 (Rh123, a substrate of P-gp), and the tested compounds [20]. The P-gp inhibitory activity of the
compounds was tested on a drug resistant cell line which overexpresses P-gp (K562Dox), by measuring
the intracellular accumulation of Rh123. After an incubation with the compounds and Rh123, cells were
washed, and the fluorescence of Rh123 was detected by flow cytometry in the FL1 channel. The drug
sensitive counterpart cells (K562) were used as control. The Rh123 accumulation ratio was calculated
as: (Mean FL1K562Dox+Compound −Mean FL1K562Dox)/Mean FL1K562Dox [30].
All the compounds tested showed weak to moderate activity, with the GI50 values ranging from
30 to 80 µM. Some differences were observed among the groups of 4 and 5. Compounds 4 were more
potent in the HCT-15 cell line but exhibited higher GI50 values in the NCI-H460 cell lines. On the other
hand, members of 5 were more potent than those of 4 in the NCI-H460 cell line. Compound 5c was the
most promising in this panel of cell lines (Table 4). The substituent at C-1 was found to influence the
inhibitory effects observed in the NCI-H460 cell. For example, 4a–d, whose C-1 bears the isopropyl
group, exhibited GI50 values ranging from 57 to 81 µM, while 5a–d, whose C-1 bears the isobutyl
group, displayed GI50 values ranging from 31 to 42 µM. These findings are in accordance with the
SAR obtained with the natural compounds in vitro antitumor assays. For instance, glyantrypine (2),
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whose C-1 bears a hydrogen atom, showed no antitumor activity (GI50 > 100 µM) while the analogue,
with the phenyl group on C-1, was more active (GI50 = 15 µM) [25]. Moreover, fumiquinazolines
F (3) and G (4), whose C-1 bears a methyl group, showed moderate activity against P-388 cells
(GI50 = 13.5 µM) [31]. Likewise, differences in the inhibitory effects against the two cell lines were
observed between enantiomeric pairs; i.e., 4a (1S,4S)/4d (1R,4R) and 4b (1S,1R)/4c (1R,4S). Significant
differences were detected for GI50 concentration values in the pair 4a/4d in NCI-H460 cells (p = 0.026).
Among the fiscalin series such as epi-fiscalin A (16, 1S,4S), epi-fiscalin C (17, 1S,4S), fiscalin F (1S,4S),
and fiscalin C (15, 1R,4S), the configurations of the stereogenic carbons of the isopropyl pyrazinone and
imidazolone moieties have already been found to influence the antitumor activity [21,32]. Although
this study brought insights into the antitumor activity of fiscalin B (4c) and the synthetic analogues,
none of the compounds showed any effect on the intracellular accumulation of Rh123, when tested at
10 µM concentrations using verapamil as a positive control for P-gp inhibition (Figure 3).
Table 4. The GI50 of 4a–d and 5a–d in the NCI-H460 and HCT-15 human tumor cell lines.
Compound
GI50 (µM)
NCI-H460 HCT-15
4a 81.33 ± 1.55 40.33 ± 3.12
4b 70.20 ± 3.15 38.15 ± 0.29
4c 57.62 ± 2.08 31.78 ± 1.21
4d 60.10 ± 2.61 33.30 ± 1.37
5a 32.52 ± 4.24 48.18 ± 2.51
5b 41.52 ± 2.52 51.94 ± 4.26
5c 31.19 ± 3.01 43.63 ± 0.25
5d 36.47 ± 3.98 47.00 ± 1.47
Values were determined with the SRB assay and are the mean± SEM of three independent experiments. Doxorubicin
was used as a positive control, with the following GI50 concentrations: 23.02 ± 0.54 nM in NCI-H460 cells,
331.49 ± 49 nM in HCT-15 cells.
Figure 3. Accumulation ratio of Rh123 in K562 and K562Dox cell lines. Cells were incubated for 1 h
with 4a–d, 5a, 5b, and 5d at a final concentration of 10 µM. The activity of 5c was not analyzed due
to its quantity we have obtained. Verapamil (10 µM) was used as a positive control (known P-gp
inhibitor), and K562 cells were used as a negative control. The accumulation ratio in the untreated
K562Dox cells was defined as zero; any value higher than that represents a potential inhibition of P-gp.
Results are the mean of two independent experiments.
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3. Materials and Methods
3.1. General Procedure
All reagents were from analytical grade. Dried pyridine and triphenylphosphite were purchased
from Sigma (Sigma-Aldrich Co. Ltd., Gillinghan, UK). Protected amino acids (ii) and anthranilic
acid (i) were purchased from TCI (Tokyo Chemical Industry Co. Ltd., Chuo-ku, Tokyo, Japan).
Column chromatography purifications were performed using flash silica Merck 60, 230–400 mesh
(EMD Millipore corporation, Billerica, MA, USA) and preparative TLC was carried out on precoated
plates Merck Kieselgel 60 F254 (EMD Millipore corporation, Billerica, MA, USA), spots were visualized
with UV light (Vilber Lourmat, Marne-la-Vallée, France). Melting points were measured in a Köfler
microscope and are uncorrected. Infrared spectra were recorded in a KBr microplate in a FTIR
spectrometer Nicolet iS10 from Thermo Scientific (Waltham, MA, USA) with Smart OMNI-Transmission
accessory (Software 188 OMNIC 8.3). 1H and 13C NMR spectra were recorded in CDCl3 (Deutero
GmbH, Kastellaun, Germany) at room temperature unless otherwise mentioned on Bruker AMC
instrument (Bruker Biosciences Corporation, Billerica, MA, USA), operating at 300 MHz for 1H
and 75 MHz for 13C). Carbons were assigned according to HSQC and or HMBC experiments.
Optical rotation was measured at 25 ◦C using the ADP 410 polarimeter (Bellingham + Stanley
Ltd., Tunbridge Wells, Kent, UK), using the emission wavelength of sodium lamp, concentrations
are given in g/100 mL. Qualitative GC-MS analyses were performed on a Trace GC 2000 Series
ThermoQuest gas chromatography (Thermo Fisher Scientific Inc., Austin, TX, USA) equipped with
ion-trap GCQ Plus ThermoQuest Finnigan mass detector (Thermo Fisher Scientific Inc., Austin, TX,
USA). Chromatographic separation was achieved using a capillary column (30 m× 0.25 mm× 0.25 µm,
cross-linked 5% diphenyl and 95% dimethyl polysiloxane) from Thermo ScientificTM (Thermo Fisher
Scientific Inc., Austin, TX, USA) and high-purity helium C-60 as carrier gas. High resolution mass
spectra (HRMS) were measured on a Bruker FTMS APEX III mass spectrometer (Bruker Corporation,
Billerica, MA, USA) recorded as ESI (Electrospray) made in Centro de Apoio Cientifico e Tecnolóxico á
Investigation (CACTI, University of Vigo, Pontevendra, Spain). The purity of synthesized compounds
was determined by reversed-phase HPLC with diode array detector (DAD) using C18 column
(Kimetex®, 2.6 EV0 C18 100 Å, 150 × 4.6 mm), and the mobile phase was methanol: water (60:40)
or acetonitrile:water (50:50). Enantiomeric ratio was determined by chiral HPLC (LCMS-2010EV,
Shimadzu, Lisbon, Portugal), employing a system equipped with a chiral column (Lux® 5 µm
Amylose-1, 250 × 4.6 mm) and UV-detection at 254 nm, mobile phase was hexane:ethanol (80:20) and
the flow rate was 0.5 mL/min.
3.2. General Conditions for the Synthesis of 4-(1H-Indol-3-ylmethyl)-1-isopropyl-2H-pyrazino[2,1-b]
quinazoline-3,6-(1H,4H)-diones (4b/4c)
In a closed vial, anthranilic acid (i) (28 mg, 200 µmol), N-Boc-L-valine (iia) for 4c or N-Boc-D-valine
(iib) for 4b (44 mg, 200 µmol), and triphenylphosphite (63 µL, 220 µmol) were added along with 1 mL of
dried pyridine. The vial was heated in heating block with stirring at 55 ◦C for 16–24 h. After cooling the
mixture to room temperature, L-tryptophan methyl ester hydrochloride (iiia) for 4b or D-tryptophan
methyl ester hydrochloride (iiib) for 4c (51 mg, 200 µmol) was added, and the mixture was irradiated
in the microwave at a constant temperature at 220 ◦C for 1.5 min. Four reaction mixtures were prepared
in the same conditions and treated in parallel. After removing the solvent with toluene, the crude
product was purified by flash column chromatography using hexane: EtOAc (60:40) as a mobile
phase. The preparative TLC was performed using CH2Cl2:Me2CO (95:5) as mobile phase. The major
compound appeared as a black spot with no fluorescence under the UV light. The desired compounds
4b/c were collected as yellow solids. Before analysis, compounds were recrystallized from methanol.
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3.2.1. (1R,4S)-4-(1H-Indol-3-ylmethyl)-1-isopropyl-2H-pyrazino[2,1-b]quinazoline-3,6-(1H,4H)-dione (4b)
Yield: 14%; m.p.: 168–169 ◦C; [α]D = +65.21 (c 0.46; CHCl3); IR vmax (KBr) 3411, 3066, 1684, 1596, 1471,
1389, 1293 cm−1; 1H NMR see Table 2; 13C NMR see Table 3; m/z (rel. intensity, %): 385.9 (M+, 2),
257.1 (29), 214.1 (3), 202.0 (7), 171.1 (10), 143.1 (4), 130.1 (100), 103.0 (18), 77.0 (16); (+)-HRESIMS m/z
387.1810 (M + H)+ (calculated for C23H22N4O2, 387.1776).
3.2.2. (1S,4R)-4-(1H-Indol-3-ylmethyl)-1-isopropyl-2H-pyrazino[2,1-b]quinazoline-3,6-(1H,4H)-dione (4c)
Yield: 8%; m.p.: 168–169 ◦C; [α]D = −248.1 (c 0.43; CHCl3); IR vmax (KBr) 3346, 3066, 1683, 1596,
1471, 1389, 1293 cm−1; 1H NMR see Table 2; 13C NMR see Table 3; m/z (rel. intensity, %): 385.9
(M+, 5), 257.1 (32), 298.9 (37), 284.2 (6), 254.0 (15), 238.8 (12), 201.8 (18), 189.0 (35), 171.1 (25),
149.1 (32), 130.1 (100), 103.0 (9), 77.0 (13); (+)-HRESIMS m/z 387.1809 (M + H)+ (calculated for
C23H22N4O2, 387.1776).
3.3. General Condition for the Synthesis of 4-(1H-Indol-3-ylmethyl)-1-isobutyl-2H-pyrazino[2,1-b]
quinazoline-3,6-(1H,4H)-diones (5b/5c)
In a closed vial, anthranilic acid (i) (28 mg, 200 µmol), N-Fmoc-L-leucine (iic) for 5c or
N-Fmoc-D-leucine (iid) for 5b (70.68 mg, 200 µmol), and triphenylphosphite (63 µL, 220 µmol) were
added along with 1 mL of dried pyridine. The vial was heated in heating block at 55 ◦C for 16–24 h.
After cooling the mixture to room temperature, we added L-tryptophan methyl ester hydrochloride
(iiia) for 5b (51 mg, 200 µmol), or D-tryptophan methyl ester hydrochloride (iiib) 5d (51 mg, 200 µmol),
and the mixture was irradiated in the microwave at a constant temperature at 220 ◦C for 1.5 min.
Four reaction mixtures were prepared in the same conditions and treated in parallel. After removing
the solvent with toluene, the mixture was purified by flash column chromatography using hexane:
EtOAc (60:40) as a mobile phase. The preparative TLC was performed using CH2Cl2:Me2CO (95:5) as
a mobile phase. The major compound appeared as a black spot with no fluorescence under UV light.
The desired compounds, 5b/5c, were collected as yellow solids. Before analysis, compounds were
recrystallized from methanol.
3.3.1. (1R,4S)-4-(1H-Indol-3-ylmethyl)-1-isobutyl-2H-pyrazino[2,1-b]quinazoline-3,6-(1H,4H)-dione (5b)
Yield: 10%; m.p.: 220 ◦C; [α]D = +89.74 (c 0.52; CHCl3); IR vmax (KBr) 3334, 3060, 1686, 1457, 1386,
1291 cm−1; 1H NMR see Table 2; 13C NMR see Table 3; (+)-HRESIMS m/z 401.1967 (M + H)+ (calculated
for C24H24N4O2, 401.1933).
3.3.2. (1S,4R)-4-(1H-Indol-3-ylmethyl)-1-isobutyl-2H-pyrazino[2,1-b]quinazoline-3,6-(1H,4H)-dione (5c)
Yield: 8%; m.p.: 219 ◦C; [α]D = −61.72 (c 0.54; CHCl3); IR vmax (KBr) 3334, 3060, 1682, 1587, 1396,
1298 cm−1; 1H NMR see Table 2; 13C NMR see Table 3; (+)-HRESIMS m/z 401.1966 (M + H)+ (calculated
for C24H24N4O2, 401.1933).
3.4. General Condition for the Synthesis of Compounds 4a and 5a
3.4.1. Synthesis of N-(2-Aminobenzoyl)-L-tryptophan methyl ester (iv-a)
To a mixture of anthranilic acid (287 mg, 2.39 mmol) and TBTU (920 mg, 2.86 mmol, 1.2 equiv)
in acetonitrile (20 mL) was added Et3N (833 µL, 4.78 mmol, 2 equiv) and L-tryptophan methyl ester
(521 mg, 2.39 mmol) at room temperature. After stirring for 5 h, the reaction mixture was concentrated
under reduced pressure. The residue was dissolved in CH2Cl2 and washed with 1 M HCl, extracted
with CH2Cl2 (3 × 100 mL), dried with Na2SO4, filtered, and concentrated. The residue was purified by
flash chromatography (eluent 1% MeOH in CH2Cl2) to yield iv-a as a white solid (675.5 mg, 96%), m.p.
134–135 ◦C, IR vmax (KBr): 3424, 1746, 1727, 1645, 1611, 1581; 1H NMR (300, MHz, CDCl3): 8.15 (s, 1H),
7.56 (d, 1H, J = 7.9 Hz), 7.35 (d, 1H, J = 8.1 Hz), 7.19–7.15 (m, 3H), 7.09 (t, 1H, J = 7.4 Hz), 7.01 (d, 1H,
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J = 2.3 Hz), 6.65 (dd, 1H, J = 8,7 and 1.1 Hz), 6.56 (ddd, 1H, J = 7.5 and 0.8 Hz), 5.08 (dt, 1H, J = 7.5
and 5.3 Hz), 3.71 (s, 3H), 3.43 (m, 2H); 13C NMR (75, MHz, CDCl3) 172.6 (CO), 168.8 (CO), 148.8 (C),
136.1 (C), 132.6 (CH), 127.6 (CH), 127.6 (C), 122.8 (CH), 122.3 (CH), 119.8 (CH), 118.7 (CH), 117.3 (CH),
116.7 (CH), 115.3 (C), 111.3 (CH), 110.1 (C), 53.1 (CH), 52.7 (CH3), 27.7 (CH2).
3.4.2. Synthesis of N-[9H-Fluoren-9-ylmethoxy)carbonyl]-L-valinyl-2-aminobenzoyl-L-tryptophan
methyl ester (vi-a)
To a solution of iv-a (160 mg, 0.474 mmol) in dried CH2Cl2 (10 mL) was added
N-Fmoc-L-valine-Cl [27] (v-a,182 mg, 0.5 mmol). The mixture was stirred for 30 min, followed by
addition of aqueous Na2CO3 (1 M, 8 mL, 8 mmol). After continuous stirring for 3 h, the mixture was
extracted with CH2Cl2 (4 × 100 mL), dried with Na2SO4, filtered, and concentrated. The residue was
purified by flash chromatography (eluent: 5% MeOH in CH2Cl2 to give vi-a as a white solid (296.4 mg,
95%), m.p.: 194.4–196.3 ◦C, [α]30D = +13.22 (c 0.126, CHCl3), IR vmax (KBr) 3318, 1727, 1698, 1588 cm−1;
1H NMR (300, MHz, CDCl3): 11.4 (s, 1H), 8.50 (d, 1H, J = 8.3 Hz), 8.24 (s, 1H), 7.67 (d, 2H, J = 7.4 Hz),
7.57 (d, 1H, J = 7.4 Hz), 7.51 (d, J = 7.3), 7.43–7.19 (m, 8H), 7.08 (t, 1H, J = 7.4 Hz), 6.97 (t, 1H, J = 7.4 Hz),
6.91 (d, 1H, J = 7.5 Hz) 6.87 (s, 1H), 6.68 (d, 1H, J = 7.6 Hz), 5.50 (d, 1H, J = 8.5 Hz), 4.97 (dd, 1H, J = 12.7
and 5.2 Hz), 4.32 (dt, 3H, J = 17.5 and 10.4 Hz), 4.20 (dt, 1H, J = 13.6 and 6.1 Hz), 3.72 (s, 3H), 3.38 (dd,
1H, J = 15.0 and 5.2 Hz), 3.31 (dd, 1H J = 14.9 and 5.3 Hz), 1.82 (m, 1H), 0.97 (d, 1H, J = 6.7 Hz), 0.90 (d,
6H, J = 6.8 Hz) 13C NMR (75, MHz, CDCl3) 172.1 (CO), 170.3 (CO), 168.3 (CO), 156.6 (C), 144.1 (2C),
141.3 (2C), 138.9 (C), 136.1 (C), 132.8 (CH), 127.7 (2CH), 127.5 (C), 127.1 (2CH), 127.1 (2CH), 127.0 (CH),
125.3 (CH), 125.2 (CH), 123.2 (CH), 122.8 (CH), 122.3 (CH), 121.4 (C), 120.0 (2CH), 119.8 (CH), 118.4 (C),
111.4 (CH), 109.6 (C), 67.3 (CH2), 61.4 (CH), 53.4 (CH), 52.6 (CH3), 47.3 (CH), 31.3 (CH), 27.3 (CH2),
19.4 (CH3), 17.6 (CH3).
3.4.3. Synthesis of (1S,4S)-4-(1H-Indol-3-ylmethyl)-1-isopropyl-2H-pyrazino[2,1-b]quinazolin-3,6-(1H,
4H)-dione (4a)
To a solution of vi-a (290 mg, 0.440 mmol) in dried CH2Cl2 (20 mL) was added Ph3P (576 mg,
2.2 mmol, 5 equiv), I2 (448 mg, 2.16 mmol. 4.9 equiv), and N,N-diisopropylethylamine (774 µL,
4.44 mmol, 10 equiv). The reaction mixture was stirred at room temperature for 5 h, quenched
with aqueous Na2CO3, and extracted with CH2Cl2 (3 × 100 mL), dried with Na2SO4, filtered and
concentrated. Hexane was added to remove an excess of Ph3P, the precipitate was filtered and was
treated with CH2Cl2 (10 mL) and piperidine (2.5 mL, 20%) at room temperature for 20 min, followed by
solvent evaporation to provide the solid which was triturated with hexane (1× 200 mL), CH2Cl2/PhMe
(1 × 200 mL), and hexane (1 × 200 mL). The vacuum-dried crude residue was dissolved in CH3CN
(10 mL) in the presence of DMAP (64 mg, 0.53 mmol) and refluxed for 19 h. The reaction mixture
was purified by preparative TLC (EtOAc: MeOH: CH2Cl2, 50:2.5:47.5) to afford 4a (45.5 g, 28%);
m.p.: 112.8–114.1 ◦C, [α]30D = +300.55 (c 0.061, CHCl3), IR vmax (KBr) 3417, 3068, 1683, 1594, 1471, 1387,
1333 cm−1; 1H NMR see Table 2; 13C NMR see Table 3; m/z (rel. intensity, %): 386.3 (M+, 8), 341.0 (5),
315 (10), 282.0 (8), 257.1 (55), 241.9 (7), 217.1 (17), 186.1 (10), 171.0 (18), 130.1 (100), 103.0 (14), 77.0 (16);
(+)-HRESIMS m/z 387.1810 (M + H)+ (calculated for C23H22N4O2, 387.1776).
3.4.4. Synthesis of N-[9H-Fluoren-9-ylmethoxy)carbonyl]-L-methylpentanyl-2H-aminobenzoyl-L-
tryptophan methyl ester (vi-b)
To a solution of compound iv-a (129 mg, 0.382 mmol) in dried CH2Cl2 (10 mL) was added
N-Fmoc-L-leucine-Cl [27] (v-b, 171 mg, 0.458 mmol). The mixture was stirred for 30 min, followed by
addition of aqueous Na2CO3 (1 M, 7.6 mL, 7.6 mmol). After being stirred for a total 3 h, the mixture
was extracted with CH2Cl2 (4 × 100 mL), dried with Na2SO4, filtered, and concentrated. The residue
was purified by flash chromatography (eluent 5% MeOH in CH2Cl2) to give vi-b as a white solid
(231.7 mg, 92%), m.p.: 193.7–194.9 ◦C, [α]30D = +18.42 (c 0.398, CHCl3), IR vmax (KBr) 3405, 1744, 1695,
1586 cm−1; 1H NMR (300, MHz, CDCl3): 11.4 (s, 1H), 8.59 (d, 1H, J 8.3 Hz), 8.19 (s, 1H), 7.76 (d, 2H,
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J 7.4 Hz), 7.65 (d, 1H, J 7.3 Hz), 7.59 (d, 1H, J 7.4 Hz), 7.52-7.28 (m, 8H), 7.17 (t, 1H, J 7.3 Hz), 7.06
(d, 1H, J 7.4 Hz), 7.00 (d, 1H, 7.7 Hz) 6.96 (s, 1H), 6.73 (d, 1H, J 7.6 Hz), 5.55 (d, 1H, J 8.5 Hz), 5.05
(dd, 1H, J 12.6 and 5.2 Hz), 4.39 (d, 2H, J 6.6 Hz), 4.28 (m, 2H), 3.72 (s, 3H), 3.38 (m, 2H), 2.33 (dt, 1H
J 13.0 and 6.4 Hz), 1.06 (d, 3H, J 6.8 Hz), 0.98 (d, 3H, J 6.8 Hz); 13C NMR (75, MHz, CDCl3): 172.1
(CO), 170.2 (CO), 168.3 (CO), 156.5 (CO), 143.8 (2C), 141.3 (2C), 139.0 (C), 136.1 (C), 132.9 (CH), 127.7
(2CH), 127.5 (C), 127.1 (2CH), 127.1 (2CH), 126.9 (CH), 125.3 (CH), 125.2 (CH), 123.2 (CH), 122.8 (CH),
122.4 (CH), 121.4 (C), 120.2 (2CH), 119.8 (CH), 118.5 (C), 111.4 (CH), 109.7 (CH), 67.2 (CH2), 61.3 (CH),
53.3 (CH), 52.6 (CH3), 38.6 (CH), 47.3 (CH2), 31.4 (CH), 27.3 (CH2), 19.4 (CH3), 17.5 (CH3).
3.4.5. Synthesis of (1S,4S)-4-(1H-Indol-3-ylmethyl)-1-isobutyl-2H-pyrazino[2,1-b]quinazolin-3,6-
(1H,4H)-dione (5a)
To a solution of vi-b (232 mg, 0.344 mmol) in dried CH2Cl2 (20 mL) was added Ph3P (451 mg,
1.72 mmol, 5 equiv), I2 (428 mg, 1.68 mmol. 4.9 equiv), and N,N-diisopropylethylamine (605 µL,
3.47 mmol, 10 equiv). The reaction mixture was stirred at room temperature for 5 h, quenched
with aqueous Na2CO3, and extracted with CH2Cl2 (3 × 100 mL), dried with Na2SO4, filtered and
concentrated. Hexane was added to remove an excess of Ph3P, the precipitate was filtered and was
treated with CH2Cl2 (10 mL) and piperidine (2.5 mL, 20%) at room temperature for 20 min, followed by
solvent evaporation to provide the solid which was triturated with hexane (1× 200 mL), CH2Cl2/PhMe
(1 × 200 mL), and hexane (1 × 200 mL). The vacuum-dried crude residue was dissolved in CH3CN
(10 mL) in the presence of DMAP (80 mg, 0.66 mmol) and refluxed for 19 h. The reaction mixture
was purified by preparative TLC (EtOAc:MeOH:CH2Cl2, 50:2.5:47.5) to afford 5a (39 mg, 28%); m.p.:
105.9–106.3 ◦C, [α]30D = +81.76 (c 0.106, CHCl3), IR vmax (KBr) 3435, 3060, 1686, 1602, 1387, 1292 cm−1;
1H NMR see Table 2; 13C NMR see Table 3; (+)-HRESIMS m/z 401.1933 (M + H)+ (calculated for
C24H24N4O2, 401.1933).
3.5. General Condition for the Synthesis Compound 4d and 5d
3.5.1. Synthesis of N-(2-Aminobenzoyl)-D-tryptophan methyl ester (iv-b)
To a mixture of anthranilic acid (287 mg, 2.39 mmol) and TBTU (920 mg, 2.86mmol, 1.2 equiv) in
CH3CN (20 mL) was added Et3N (833 µL, 4.78 mmol, 2 equiv) and D-tryptophan methyl ester (521 mg,
2.39 mmol) at room temperature with stirring. After being stirred for 5 h, the reaction mixture was
concentrated under reduced pressure. The residue was dissolved in CH2Cl2 and washed with 1M
HCl, extracted with CH2Cl2 (3 × 100 mL), dried with Na2SO4, filtered and concentrated. The residue
was purified by flash chromatography (eluent: 1% MeOH in CH2Cl2) to yield iv-b as a white solid
(569.7 mg, 81%), m.p. 131.9–134.3 ◦C, IR vmax (KBr) 3423, 1746, 1644 cm−1, 1H NMR (300, MHz, CDCl3):
8.14 (s, 1H), 7.56 (d, 1H, J = 7.9 Hz), 7.35 (d, 1H, J = 8.1 Hz), 7.19–7.15 (m, 3H), 7.10 (ddd, 1H, J = 8.0,
7.1, and 1.1 Hz), 7.01 (d, 1H, J = 2.4 Hz), 6.65 (dd, 1H, J = 8,7 and 1.1), 6.60 (s, 1H), 6.59–6.52 (ddd, 2H,
J = 7.5 and 0.8 Hz), 5.08 (dt, 1H, J = 7.5 and 5.3 Hz), 3.72 (s, 3H), 3.43 (m, 2H); 13C NMR (75, MHz,
CDCl3): 172.6 (CO), 168.8 (CO), 148.8 (C), 136.1 (C), 132.6 (CH), 127.6 (CH), 127.5 (C), 122.8 (CH),
122.3 (CH), 119.8 (CH), 118.7 (CH), 117.3 (CH), 116.7 (CH), 115.3 (C), 111.3 (CH), 110.1 (C), 53.1 (CH),
52.5 (CH3), 27.7 (CH2).
3.5.2. Synthesis of N-[9H-Fluoren-9-ylmethoxy)carbonyl]-D-valinyl-2-aminobenzoyl-D-tryptophan
methyl ester (vi-c)
To a solution of iv-b (140 mg, 0.416 mmol) in dried CH2Cl2 (10 mL) was added
N-Fmoc-D-valine-Cl [27] (v-c,182 mg, 0.5 mmol). The mixture was stirred for 30 min, followed
by addition of aqueous Na2CO3 (1 M, 8 mL, 8 mmol). After continuous stirring for 3 h, the mixture was
extracted with CH2Cl2 (4 × 100 mL), dried with Na2SO4, filtered, and concentrated. The residue was
purified by flash chromatography (eluent: 5% MeOH in CH2Cl2 to give vi-c as a white solid (220.4 mg,
84%), m.p.: 197.8–200.2 ◦C, [α]30D = −22.72 (c 0.088, CHCl3), IR vmax (KBr) 3423, 1724, 1670, 1589 cm−1;
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1H NMR (300, MHz, CDCl3): 11.42 (s, 1H), 8.59 (d, 1H, J = 8.3 Hz), 8.18 (s, 1H), 7.76 (d, 2H, J = 7.4 Hz),
7.66 (d, 1H, J = 7.3 Hz), 7.60 (d, 1H, J = 7.3 Hz); 7.53–7.28 (m, 9H), 7.17 (t, 1H, J = 7.3 Hz), 7.08 (d, 1H,
J = 7.4 Hz), 7.02 (m, 1H), 6.96 (s, 1H), 6.72 (d, 1H, J = 7.6 Hz), 5.55 (d, 1H, J = 8.5 Hz), 5.06 (dd, 1H,
J = 12.5 and 5.2 Hz), 4.40 (d, 1H, J = 6.6 Hz), 4.32–4.24 (m, 1H), 3.73 (s, 3H), 3.45–3.31 (m, 2H), 1.65 (s,
3H) 2.40–2.31 (m, 1H), 1.06 (d, 3H, J = 6.8 Hz), 0.98 (d, 3H, J = 6.9 Hz); 13C NMR (75, MHz, CDCl3)
172.0 (CO), 170.2 (CO), 168.3 (CO), 156.5 (C), 144.1 (2C), 141.3 (2C), 139.0 (C), 136.1 (C), 132.9 (CH),
127.7 (2CH), 127.5 (C), 127.1 (2CH), 127.1 (2CH), 126.9 (CH), 125.3 (CH), 125.2 (CH), 123.2 (CH), 122.8
(CH), 122.4 (CH), 121.4 (C), 120.2 (2CH), 119.8 (CH), 118.5 (C), 111.4 (CH), 109.7 (C), 67.2 (CH2), 61.3
(CH), 53.3 (CH), 52.6 (CH3), 47.3 (CH), 31.3 (CH), 27.3 (CH2), 19.4 (CH3), 17.6 (CH3).
3.5.3. Synthesis of (1R,4R)-4-(1H-Indol-3-ylmethyl)-1-isopropyl-2H-pyrazino[2,1-b]quinazolin-3,6-
(1H,4H)-dione (4d)
To a solution of vi-c (183 mg, 0.278 mmol) in dried CH2Cl2 (20 mL) was added Ph3P (365 mg,
1.4 mmol, 5 equiv), I2 (345 mg, 1.36 mmol, 4.9 equiv), and N,N-diisopropylethylamine (489 µL,
2.81 mmol, 10 equiv). The reaction mixture was stirred at room temperature for 5 h, quenched
with aqueous Na2CO3, and extracted with CH2Cl2 (3 × 100 mL), dried with Na2SO4, filtered, and
concentrated. Hexane was added to remove an excess of Ph3P, the precipitate was filtered and
treated with CH2Cl2 (10 mL) and piperidine (2.5 mL, 20%) at room temperature for 20 min, followed by
solvent evaporation to provide the solid which was triturated with hexane (1× 200mL), CH2Cl2/PhMe
(1 × 200 mL), and hexane (1 × 200 mL). The vacuum-dried crude residue was dissolved in CH3CN
(10 mL in the presence of DMAP (64 mg, 0.53 mmol) and refluxed for 19 h. The reaction mixture was
purified by preparative TLC (EtOAc:MeOH:CH2Cl2, 50:2.5:47.5) to afford 4d (22.4 mg, 21%), m.p.:
111.9–113.0 ◦C, [α]30D = −210.53 (c 0.114, MeOH), IR vmax (KBr) 3321, 3068, 1683, 1593, 1471, 1387, 1291
cm−1; 1H NMR see Table 2; 13C NMR see Table 3; m/z (rel. intensity, %): 385.9 (M+, 12), 257.1 (29),
214.1 (3), 202.0 (7), 171.1 (10), 143.1 (4), 130.1 (100), 103.0 (18), 77 (16); (+)-HRESIMS m/z 389.1776 (M +
H)+ (calculated for C23H22N4O2, 387.1809).
3.5.4. Synthesis of N-[9H-Fluoren-9-ylmethoxy)carbonyl]-D-methylpentyl-2-aminobenzoyl-D-
tryptophan methyl ester (vi-d)
To a solution of iv-b (130 mg, 0.386 mmol) in dried CH2Cl2 (10 mL) was added
N-Fmoc-D-leucine-Cl [27] (v-d,172.5 mg, 0.464 mmol). The mixture was stirred for 30 min, followed by
addition of aqueous Na2CO3 (1 M, 7.7 mL, 7.7 mmol). After continuous stirring for 3 h, the mixture
was extracted with CH2Cl2 (4×), dried with Na2SO4, filtered, and concentrated. The residue was
purified by flash chromatography (eluent: 5% MeOH in CH2Cl2) to give vi-d as a white solid (251 mg,
98%), m.p.: 194.9–196.3 ◦C, [α]30D = −31.75 (c 0.105, CHCl3), IR vmax (KBr) 1740, 1645, 1584 cm−1; 1H
NMR (300, MHz, CDCl3): 11.5 (s, 1H), 8.58 (d, 1H, J = 8.3 Hz), 8.23 (s, 1H), 7.76 (d, 2H, J = 7.4 Hz),
7.66 (d, 1H, J = 7.4 Hz), 7.57 (d, 1H, J = 7.4 Hz), 7.51–7.26 (m, 8H), 7.16 (t, 1H, J = 7.4 Hz), 7.07 (d, 1H,
J = 7.4 Hz), 7.00 (t, 1H, J = 7.5 Hz) 6.93 (s, 1H), 6.74 (d, 1H, J = 7,6 Hz), 5.43 (d, 1H, J = 7.9 Hz), 5.04 (dd,
1H, J = 12.7 and 5.2 Hz), 4.41 (dt, 3H, J = 17.5 and 10.4 Hz), 4.25 (t, 1H, J = 7.0 Hz), 3.72 (s, 3H), 3.38 (dd,
1H, J = 15.0 and 5.2 Hz), 3.31 (dd, 1H J = 14.9 and 5.3 Hz), 1.82 (m, 1H), 1.00 (d, 6H, J = 6.2 Hz); 13C
NMR (75 MHz, CDCl3): 172.1 (CO), 170.2 (CO), 168.3 (CO), 156.4 (CO), 143.8 (2C), 141.3 (2C), 139.0 (C),
136.1 (C), 132.9 (CH), 127.7 (2CH), 127.5 (C), 127.1 (2CH), 127.1 (2CH), 126.9 (CH), 125.3 (CH), 125.2
(CH), 123.2 (CH), 122.8 (CH), 122.4 (CH), 121.4 (C), 120.2 (2CH), 119.8 (CH), 118.5 (C), 111.4 (CH), 109.7
(CH), 67.2 (CH2), 61.3 (CH), 53.3 (CH), 52.6 (CH3), 47.3 (CH2), 38.6 (CH), 31.4 (CH), 27.3 (CH2), 19.4
(CH3), 17.5 (CH3).
3.5.5. Synthesis of (1R,4R)-4-(1H-Indol-3-ylmethyl)-1-isobutyl-2H-pyrazino[2,1-b]quinazolin-3,6-
(1H,4H)-dione (5d)
To a solution of vi-d (251 mg, 0.373 mmol) in dried CH2Cl2 (20 mL) was added Ph3P (489 mg,
1.9 mmol, 5 equiv), I2 (464 mg, 1.83 mmol, 4.9 equiv), and N,N-diisopropylethylamine (656 µL,
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3.77 mmol, 10 equiv). The reaction mixture was stirred at room temperature for 5 h, quenched
with aqueous Na2CO3, and extracted with CH2Cl2 (3 × 100 mL), dried with Na2SO4, filtered, and
concentrated. Hexane was added to remove an excess of Ph3P, the precipitate was filtered and was
treated with CH2Cl2 (10 mL) and piperidine (2.5 mL, 20%) at room temperature for 20 min, followed by
solvent evaporation to provide the solid which was triturated with hexane (1× 200 mL), CH2Cl2/PhMe
(1 × 200 mL), and hexane (1 × 200 mL). The vacuum-dried crude residue was dissolved in CH3CN
(10 mL in the presence of DMAP (84 mg, 0.82 mmol) and refluxed for 19 h. The reaction mixture was
purified by preparative TLC (EtOAc:MeOH:CH2Cl2, 50:2.5:47.5) to afford 5d (61.6 mg, 40%), m.p.:
103.2–105.6 ◦C, [α]30D = −186.04 (c 0.086, CHCl3), IR vmax (KBr) 3333, 3061, 1687, 1603, 1296 cm−1;
1H NMR see Table 2; 13C NMR see Table 3; (+)-HRESIMS m/z 401.1966 (M + H)+ (calculated for
C24H24N4O2, 401.1933).
3.6. Screening Test for Antitumor and Anti-P-Glycoprotein Activity
Compounds 4a–d and 5a–d were reconstituted in sterile DMSO to the final concentration of 60
mM, and several aliquots were made and stored at −20 ◦C to avoid repeated freeze-thaw cycles. For
experiments, the compounds were freshly diluted in medium to the desired concentration. Screening
for tumor cell growth inhibition was carried out in two human tumor cell lines (NCI-H460 and
HCT-15), with the sulforhodamine B (SRB) assay, as previously described [30]. Briefly, tumor cells
were plated in 96-well plates, incubated at 37 ◦C for 24 h, and then treated for 48 h with 5 serial
dilutions (1:2) of each compound (ranging from 150 µM to 9.375 µM). The effect of the vehicle solvent
(DMSO) was also analyzed as a control. Cells were fixed with 10% ice-cold trichloroacetic acid,
washed with water and stained with SRB. Finally, the plates were washed with 1% acetic acid and
the bound SRB was solubilized with 10 mM Tris Base. Absorbance was measured in a microplate
reader (Synergy Mx, Biotek Instruments Inc., Winooski, VT, USA) at 510 nm. For each compound,
the corresponding GI50 (concentration which inhibited 50% of net cell growth) was determined, as
previously described [33]. For the screening of compounds for drug-efflux inhibitory activity, the
flow cytometry determination of rhodamine-123 cellular accumulation was carried out as previously
described [34]. Briefly, K562 and K562Dox cells were incubated for 1 h at 37 ◦C with 20 µM of the
compounds, and 1 µM of rhodamine-123 (Rh123, from Sigma, USA). Verapamil was used as a positive
control. Cells were then washed, resuspended in ice cold PBS, and analyzed in a BD Accuri™ C6
Flow Cytometer (BD Biosciences, San Jose, CA, USA). Data were analyzed using the FlowJo software
(version 7.6.1, Tree Star, Inc.). The ratio of Rh123 accumulation in the cells was then calculated as
MFIK562Dox+Compound -MFIK562Dox)/MFIK562Dox [30].
4. Conclusions
Inspired by the marine-derived fiscalin B (4c), quinazolinone alkaloid derivatives were
synthesized using two different methodologies: a highly efficient and straightforward three-component
one-pot microwave-assisted approach and also a multistep Mazurkiewicz–Ganesan approach. While
the former proved to be efficient and practical for broad screening libraries of the compounds, the latter,
although with a more intricate methodology, proved to be a good approach for the synthesis of the
syn enantiomers. Moreover, we have found that partial epimerization under the reaction conditions
could occur. In vitro growth inhibitory activity of two tumor cell lines revealed that among this series
of synthesized compounds, six new analogues were found to exhibit tumor cell growth inhibitory
activity. Consequently, this marine-inspired synthesis can bring new insights into discovery of new
lead compounds in the oncology area.
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